Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > T2 Biosystems Announces the Presentation of Data on Direct Detection with T2Candida —Data Presented at Infectious Disease Society of America—

Abstract:
T2 Biosystems, a company developing direct detection products for superior diagnostics, today announced the presentation of data on its T2MR platform for detection of infectious diseases at the 49th Annual Meeting of the Infectious Disease Society of America (IDSA) in Boston, MA, October 20-23, 2011. Two independent research groups from Massachusetts General Hospital and University of Houston College of Pharmacy used the T2MR platform to analyze whole blood specimens from patients with 5 different types of Candida spp. infections. The T2MR platform provided rapid, sensitive, and specific Candida species detection results from whole blood samples compared with current detection methods.

T2 Biosystems Announces the Presentation of Data on Direct Detection with T2Candida —Data Presented at Infectious Disease Society of America—

Lexington, MA | Posted on October 22nd, 2011

The presentations at IDSA analyzed infected patient samples using the T2Candida assay on the T2MR platform. The results from Massachusetts General Hospital and University of Houston College of Pharmacy were both in concordance with blood culture, providing species-specific results in roughly two hours. "These results demonstrate the high specificity and sensitivity of T2 Bio's diagnostic technology, which may be applied to any immunoassay or molecular target," said Kevin Garey, Chair, Department of Clinical Sciences and Administration at the University Of Houston College Of Pharmacy. "These data also highlight the potential of the T2Candida assay to dramatically reduce morbidity and mortality associated with candidemia by enabling physicians to rapidly deliver appropriately targeted therapy."

"These new data further demonstrate that the T2MR platform can dramatically speed up identification of candidemia in patients with Candida infections, which we believe will result in truly meaningful clinical benefits," said John McDonough, CEO of T2 Biosystems. "These results also highlight the tremendous potential for automated detection of targets on the T2MR platform, enabling a wide range of accurate and efficient disease detection for improved response time and treatments. We expect to initiate a large-scale clinical trial of the T2Candida assay and the T2Dx instrument in 2012, and we are actively expanding our T2 molecular and immunoassay pipelines while pursuing optimal partnerships to apply our technology to additional areas of medical need."

Candida is a blood-borne pathogen associated with approximately 90,000 cases of candidemia in the US annually. Currently, candidemia has an approximate 40% mortality rate, largely due to the elapsed time from Candida infection to positive diagnosis and treatment. Current detection methods rely on blood culture, a process that can take two to five days before identifying a Candida infection. The T2MR platform is able to detect Candida directly from whole blood without the limits experienced with optical detection technology, even at low copy numbers, and provide results within two hours.

Presentations at IDSA

Saturday, October 22, 2011, 11:45 AM - 1:45 PM ET, Poster Hall B1, #1024: Clinical assessment of nanotechnology and miniaturized magnetic resonance to detect candidemia in hospitalized patients by Kevin W. Garey, PharmD, MS, University of Houston College of Pharmacy

Saturday, October 22, 2011, 11:45 AM - 1:45 PM ET, Poster Hall B1, #1026: Diagnosis of sequential candidemia with the use of NMR biosensor by Eleftherios Mylonakis, MD, PhD, Massachusetts General Hospital

####

About T2 Biosystems
T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR, the Company’s proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate, and rapid assay results. The Company’s products detect molecular or immunoassay targets directly from unpurified clinical samples in hospitals, labs and physicians’ offices.

For more information, please click here

Contacts:
MacDougall Biomedical Communications
Chris Erdman
781-235-3060

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanomedicine

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Events/Classes

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Leti Will Present 11 Papers and Host More-than-Moore Technologies Workshop November 14th, 2017

TUBALL nanotube-based concentrates recognised as the most innovative raw material for composites by JEC Group November 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project